Ginkgo Bioworks Holdings (DNA) Stock Forecast & Price Target

Compare

2,286 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DNA Analyst Ratings

Moderate Sell

1 Buy

0 Hold

2 Sell

Based on 3 analysts giving stock ratings to

Ginkgo

Bioworks Holdings

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DNA Stock 12 Month Forecast

Average Price Target

$14.00

▲(57.84% Upside)

Based on 3 Wall Street analysts offering 12 month price targets for Ginkgo Bioworks Holdings in the last 3 months. The average price target is $14.00 with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 57.84% change from the last price of $8.87.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","6.75":"$6.75","9.5":"$9.5","12.25":"$12.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$14.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$14.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,6.75,9.5,12.25,15],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.65,9.061538461538461,9.473076923076924,9.884615384615385,10.296153846153846,10.707692307692309,11.11923076923077,11.53076923076923,11.942307692307693,12.353846153846154,12.765384615384615,13.176923076923078,13.588461538461539,{"y":14,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.65,9.061538461538461,9.473076923076924,9.884615384615385,10.296153846153846,10.707692307692309,11.11923076923077,11.53076923076923,11.942307692307693,12.353846153846154,12.765384615384615,13.176923076923078,13.588461538461539,{"y":14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.65,9.061538461538461,9.473076923076924,9.884615384615385,10.296153846153846,10.707692307692309,11.11923076923077,11.53076923076923,11.942307692307693,12.353846153846154,12.765384615384615,13.176923076923078,13.588461538461539,{"y":14,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":9.61,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.82,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.24,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.66,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.96,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":11.36,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":11.02,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":14.67,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.99,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.65,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$14.00

Average Price Target$14.00

Lowest Price Target$14.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matt Larew

William Blair

Sell

―

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Emergent Biosolutions (NYSE: EBS) and Ginkgo Bioworks Holdings (NYSE: DNA)

Brendan Smith

TD Cowen

$18→$14

Buy

57.84%

Upside

Reiterated

11/07/25

Ginkgo Bioworks Holdings: Strategic Growth Amid Revenue Decline Justifies Buy Rating

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

Sell

―

Reiterated

11/07/25

Bank of America Securities Remains a Sell on Ginkgo Bioworks Holdings (DNA)

Mark Massaro

BTIG

$6→$9

Sell

1.47%

Upside

Reiterated

08/25/25

BTIG Sticks to Its Sell Rating for Ginkgo Bioworks Holdings (DNA)

Tejas Savant

Morgan Stanley

$10

Hold

12.74%

Upside

Reiterated

05/28/25

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (NYSE: DNA) and Elanco Animal Health (NYSE: ELAN)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

Sell

-9.81%

Downside

Reiterated

05/19/25

We tweak our model and reiterate our Underperform rating pending further evidence that DNA can successfully complete its various ongoing operational initiatives. Our DCF-based PO remains at $8...

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

Sell

-9.81%

Downside

Reiterated

03/03/25

We update our model, and our PO remains $8 based on DCF (14% WACC & 4% terminal growth rate). We reiterate our Underperform rating.

Matthew Sykes

Goldman Sachs

Sell

-21.08%

Downside

Reiterated

02/25/25

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (NYSE: DNA), Thermo Fisher (NYSE: TMO) and Option Care Health (NASDAQ: OPCH)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matt Larew

William Blair

Sell

―

Reiterated

11/10/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NASDAQ: NAMS), Emergent Biosolutions (NYSE: EBS) and Ginkgo Bioworks Holdings (NYSE: DNA)

Brendan Smith

TD Cowen

$18→$14

Buy

57.84%

Upside

Reiterated

11/07/25

Ginkgo Bioworks Holdings: Strategic Growth Amid Revenue Decline Justifies Buy Rating

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

Sell

―

Reiterated

11/07/25

Bank of America Securities Remains a Sell on Ginkgo Bioworks Holdings (DNA)

Mark Massaro

BTIG

$6→$9

Sell

1.47%

Upside

Reiterated

08/25/25

BTIG Sticks to Its Sell Rating for Ginkgo Bioworks Holdings (DNA)

Tejas Savant

Morgan Stanley

$10

Hold

12.74%

Upside

Reiterated

05/28/25

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (NYSE: DNA) and Elanco Animal Health (NYSE: ELAN)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

Sell

-9.81%

Downside

Reiterated

05/19/25

We tweak our model and reiterate our Underperform rating pending further evidence that DNA can successfully complete its various ongoing operational initiatives. Our DCF-based PO remains at $8...

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

Sell

-9.81%

Downside

Reiterated

03/03/25

We update our model, and our PO remains $8 based on DCF (14% WACC & 4% terminal growth rate). We reiterate our Underperform rating.

Matthew Sykes

Goldman Sachs

Sell

-21.08%

Downside

Reiterated

02/25/25

Analysts Offer Insights on Healthcare Companies: Ginkgo Bioworks Holdings (NYSE: DNA), Thermo Fisher (NYSE: TMO) and Option Care Health (NASDAQ: OPCH)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Ginkgo Bioworks Holdings

1 Month

xxx

Success Rate

6/9 ratings generated profit

Average Return

+5.27%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +5.27% per trade.

3 Months

xxx

Success Rate

9/20 ratings generated profit

Average Return

-5.60%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 45.00% of your transactions generating a profit, with an average return of -5.60% per trade.

1 Year

Brendan SmithTD Cowen

Success Rate

3/9 ratings generated profit

Average Return

-5.24%

reiterated a buy rating 2 months ago

Copying Brendan Smith's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -5.24% per trade.

2 Years

xxx

Success Rate

4/9 ratings generated profit

Average Return

-8.06%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of -8.06% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNA Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DNA has received 2 Buy Ratings, 5 Hold Ratings, and 4 Sell Ratings. DNA average Analyst price target in the past 3 months is 14.00.

Each month's total comprises the sum of three months' worth of ratings.

DNA Financial Forecast

DNA Earnings Forecast

Next quarter’s earnings estimate for DNA is -$1.46 with a range of -$1.80 to -$1.12. The previous quarter’s EPS was -$1.45. DNA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year DNA has Performed in-line its overall industry.

DNA Sales Forecast

Next quarter’s sales forecast for DNA is $37.19M with a range of $35.57M to $39.50M. The previous quarter’s sales results were $38.84M. DNA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year DNA has Performed in-line its overall industry.

DNA Stock Forecast FAQ

What is DNA’s average 12-month price target, according to analysts?

Based on analyst ratings, Ginkgo Bioworks Holdings’s 12-month average price target is 14.00.

What is DNA’s upside potential, based on the analysts’ average price target?

Ginkgo Bioworks Holdings has 57.84% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DNA a Buy, Sell or Hold?

Ginkgo Bioworks Holdings has a consensus rating of Moderate Sell which is based on 1 buy ratings, 0 hold ratings and 2 sell ratings.

What is Ginkgo Bioworks Holdings’s price target?

The average price target for Ginkgo Bioworks Holdings is 14.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $14.00 ,the lowest forecast is $14.00. The average price target represents 57.84% Increase from the current price of $8.87.

What do analysts say about Ginkgo Bioworks Holdings?

Ginkgo Bioworks Holdings’s analyst rating consensus is a Moderate Sell. This is based on the ratings of 3 Wall Streets Analysts.

How can I buy shares of DNA?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Ginkgo Bioworks Holdings (DNA) Stock Forecast & Price Target

DNA Analyst Ratings

DNA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Ginkgo Bioworks Holdings

DNA Analyst Recommendation Trends

DNA Financial Forecast

DNA Earnings Forecast

DNA Sales Forecast

DNA Stock Forecast FAQ

Detailed List of Analyst Forecasts